Mikhail Kosiborod

As Senior Vice President Late-Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, my focus is to transform AstraZeneca’s worldclass CVRM pipeline into medicines that can improve the lives of people living with these disabling conditions. Cardiovascular disease, kidney disease, Type 2 diabetes and obesity represent the largest global public health threats, but advances in science are enabling new treatment approaches that could dramatically improve care and patient outcomes. Ensuring that we have the clinical development strategies that are grounded in emerging science, disease biology and patient needs, addressing the interconnected nature of these chronic conditions, and disrupting the current paradigm that is mired in clinical inertia could prolong and improve lives for more people than ever before.

As a physician who treated thousands of patients during my career, I appreciated the inter-related nature of cardiovascular, kidney and metabolic diseases early on. Ultimately, this influenced my career as a clinical trialist, developing novel treatments that can improve not just the manifestations of these conditions, but address the root causes that drive their complications. Ultimately, my work has contributed to understanding the impact of sodium-glucose co-transporter-2 inhibition (SGLT2i) and GLP-1 receptor agonism in improving patient outcomes, representing some of the most important advances in clinical medicine in the last two decades. My work contributed to the Science Magazine Scientific Breakthrough of the Year, and one of the Top Advances in Cardiovascular Disease by the American Heart Association in 2023. I have served as a Principal Investigator of multiple investigator-initiated trials and global late-stage development programs, authored and co-authored more than 500 peer-reviewed publications, and contributed to the development of key strategies for managing diabetes, heart disease and kidney disease that have been implemented worldwide.

I joined AstraZeneca after practicing academic medicine for over 20 years. Previously, I served as Vice President of Research at Saint Luke’s Health System, where I was recognised as the inaugural Ben McCallister, MD, Endowed Chair in Cardiovascular Research and founding Executive Director of the non-for-profit Cardiometabolic Center Alliance. I also hold a Professorship in Medicine at the University of Missouri-Kansas City School of Medicine.

I earned my medical degree from Mount Sinai School of Medicine and completed my residency and cardiology fellowship at Yale University School of Medicine. I received advanced training in clinical epidemiology, clinical research and health policy through the Robert Wood Johnson Clinical Scholars Program.